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Background: Aberrant neuron/glia interactions can contribute to a variety of neurodegenerative diseases and we
have previously demonstrated that enhanced activation of Erb B2, which is a member of the epidermal growth
factor receptor (EGFR) family, can contribute to the development of diabetic peripheral neuropathy (DPN). In
peripheral nerves, Erb B receptors are activated by various members of the neuregulin-1 (NRG1) family including
NRG1 Type I, NRG1 Type II and NRG1 Type III to regulate Schwann cell (SC) growth, migration, differentiation and
dedifferentiation. Alternatively, Erb B2 activity can be negatively regulated by association with the Erb B2-interacting
protein, erbin. Since the effect of diabetes on the expression of NRG1 isoforms and erbin in peripheral nerve are
unknown, the current study determined whether changes in NRG1 isoforms and erbin may be associated with
altered Erb B2 signaling in DPN.
Results: Swiss Webster mice were rendered diabetic with streptozotocin (STZ) and after 12 weeks of diabetes,
treated with erlotinib, an inhibitor of Erb B2 activation. Inhibition of Erb B2 signaling partially reversed several
pathophysiologic aspects of DPN including a pronounced sensory hypoalgesia, nerve conduction velocity deficits
and the decrease in epidermal nerve fiber innervation. We also observed a decrease of NRG1 Type III but an
increase of NRG1 Type I level in diabetic sural nerves at early stage of diabetes. With disease progression, we
detected reduced erbin expression and enhanced MAPK pathway activity in diabetic mice. Inhibition of Erb B2
receptor suppressed MAPK pathway activity in treated-diabetic sural nerves.
Conclusions: These results support that hyperglycemia may impair NRG1/Erb B2 signaling by disrupting the
balance between NRG1 isoforms, decreasing the expression of erbin and correspondingly activating the MAPK
pathway. Together, imbalanced NRG1 isoforms and downregulated erbin may contribute to the dysregulation of
Erb B2 signaling in the development of DPN.
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Diabetic peripheral neuropathy (DPN) is one of the most
prevalent complications of chronic diabetes and is the
leading cause of non-traumatic lower limb amputation [1].
DPN patients often present with spontaneous positive
(burning, itching, abnormal sensation to temperature,
pain) or negative (numbness, insensitivity) sensory symp-
toms that are observed in a distal-to-proximal manner [2].
DPN patients often exhibit a reduction in nerve conduc-
tion velocity, loss of nerve fibers and segmental demyelin-
ation [2,3]. Mechanistically, the development of DPN has
multiple contributing factors. Hyperglycemia induces oxi-
dative stress and alters several metabolic and vascular
pathways that contribute to an increase in formation of
advanced glycation end-products, excessive polyol synthe-
sis, enhanced protein kinase C activation and an increase
in poly-ADP ribose polymerase activity [4]. Another po-
tential mechanism is altered neurotrophism since hyper-
glycemia can damage peripheral nerves by changing the
expression, proteolytic cleavage, axonal transport and
function of growth factors. For instance, diabetic rats
showed decreased retrograde axonal transport of nerve
growth factor (NGF) and brain-derived neurotrophic fac-
tor (BDNF), members of the neurotrophin family [5]. In
addition, insulin-like growth factors affect neuronal sur-
vival, growth and regeneration and are decreased in nerve
of diabetic rats [6]. Neuregulin 1 (NRG1) is a growth fac-
tor that interacts with Erb B receptors, which localize pri-
marily to Schwann cells (SC), and is critical for both SC
differentiation and degeneration. However, little is known
about how diabetes may affect gliotrophic signaling by al-
tering NRG1 levels and Erb B2 signaling in the peripheral
nervous system (PNS).
The NRG1 family comprises more than 30 membrane-
bound and secreted proteins generated by alternative
promoter usage and extensive RNA splicing [7]. The
NRG1 family is subdivided into six major isoforms based
on distinct amino termini but NRG1 Types I, II, and III
are the best characterized in the peripheral nervous sys-
tem. However, all NRG1 family members have an epider-
mal growth factor (EGF)-like domain which is sufficient
and necessary to activate the Erb B members of the EGF
receptor (EGFR) family [8]. The EGFR family contains
four members, EGFR, Erb B2, Erb B3 and Erb B4. Erb
B2 is a ligand-less receptor and Erb B3 has no tyrosine
kinase activity. In adult SCs, NRG1 binding to Erb B3
induces formation of primarily Erb B2 and Erb B3
heterodimers [9]. Receptor dimerization activates the in-
trinsic tyrosine kinase activity of Erb B2 which initiates
downstream signaling pathways.
NRG1/Erb B signaling guides every developmental
stage of the SC lineage, such as promoting the gliogenic
fate of neural crest cells, migration of SC precursors and
subsequent proliferation, survival, and differentiation[8,10]. Physiologically, the axonal expression of NRG1
Type III is necessary to promote myelination and regu-
late myelin thickness in vivo [11,12]. Moreover, disrup-
tion of Erb B signaling by transgenic overexpression of a
dominant-negative Erb B4 receptor resulted in abnormal
myelin formation, disrupted Remak bundle structure,
and neuropathic changes in both myelinated [13] and
unmyelinated [14] sensory fibers. Interestingly, patho-
logic activation of Erb B2 following axotomy can also
promote SC dedifferentiation and demyelination [15].
Though NRG1 Type III promotes myelination, NRG1
Type I and NRG1 Type II have been shown to induce
demyelination in vitro [16] and this dedifferentiation re-
sponse is tightly linked to the activation of the p42/p44
MAPK pathway [17,18]. Therefore, changes in the ex-
pression of isoforms of NRG1 may provide one mechan-
ism for activation of Erb B2 and p42/p44 MAPK
signaling in pathophysiologic states linked to neuropathy
and myelin degeneration. Furthermore, Erb B2 is also
negatively regulated by the Erb B2-interacting protein
(erbin), a downstream adapter protein that specifically
interacts with Erb B2, but not Erb B3 or Erb B4 [19]. Erbin
is mostly expressed in regions where myelination is abun-
dant and erbin null mice have hypomyelinated periph-
eral nerves, suggesting it is necessary for normal myelin
thickness of peripheral nerves [20]. Following recruit-
ment to Erb B2, erbin can inhibit the p42/p44 MAPK
pathway and potentially antagonize NRG1-induced
demyelination.
We have previously demonstrated that a transient in-
crease in Erb B2 receptor activation contributed to
diabetes-induced sensory neuropathy since inhibiting
Erb B2 signaling reversed some of the pathophysiologic
features of DPN [21]. Therefore, disrupted Erb B2 sig-
naling might contribute to the axonal degeneration and
SC demyelination in diabetic nerves. However, it re-
mains unknown whether the increase in Erb B2 activity
in diabetic nerves is associated with changes in NRG1
isoforms and erbin that may serve as positive and nega-
tive regulators of Erb B2 signaling, respectively.
To elucidate the role of altered NRG1/Erb B2 signaling
in DPN, we used diabetic Swiss Webster mice, which
after prolonged diabetes develop severe pathophysiologic
symptoms of DPN [22]. We report that diabetes altered
the expression of NRG1 Type III and NRG1 Type I in
distal nerve fibers with increasing duration of diabetes.
In particular, a decrease in NRG1 Type III expression
was accompanied by an increased expression of NRG1
Type I level in diabetic sural nerves. Additionally, the
levels of erbin were decreased in sciatic nerves of dia-
betic mice and this corresponded with an increase in
p42/p44 MAPK pathway activity. These data are the first
to characterize that diabetes can alter the expression of
proteins that serve as positive and negative regulators of
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may contribute to SC pathology in DPN.
Results
Erb B2 receptor inhibitor attenuates pathophysiological
indices of DPN
Swiss Webster mice were rendered diabetic with STZ and
changes in mechanical and thermal sensitivity were moni-
tored for 12 weeks to assess the onset of hypoalgesia in
both myelinated (mechanical) and unmyelinated (ther-
mal) nerve fibers. Diabetes induced a clear mechanical
(Figure 1A) and thermal (Figure 1B) hypoalgesia and
after 12 weeks this was associated with a significant de-
crease in both motor (MNCV) and sensory (SNCV)
nerve conduction velocity compared to non-diabetic
animals (Figure 1C and D). To address whether Erb B2
signaling contributed to the sensory deficits, mice were
treated at week 13 with vehicle or 25 mg/kg erlotinib,
which is a clinically approved inhibitor of the EGFR
that can also inhibit Erb B2 receptors [21]. The miceFigure 1 Inhibition of Erb B2 attenuated NCV and sensory deficits in
two weeks of diabetes, mechanical (A) and thermal sensitivity (B) were ass
versus time-matched STZ + Veh). Assessment of MNCV (C) and SNCV (D) in
confirmed the onset of nerve dysfunction prior to drug treatment. At 13 w
once per week for 4 weeks (solid arrow) and then twice per week (dashed
significantly improved mechanical and thermal sensitivity and decreased th
diabetic mice (**, p < 0.01; ***, p < 0.001).were initially given one treatment per week for 4 weeks
and this modestly improved mechanical and thermal
sensitivity. Increasing the frequency of dosing to twice
per week (Figure 1A and B, dashed arrows) yielded a
greater improvement in mechanical sensitivity, but
thermal sensitivity did not change beyond that seen
with a single dose per week. After 8 weeks of erlotinib
treatment, the pre-existing deficits in both MNCV and
SNCV were partially reversed (Figure 1C and D). Inter-
estingly, the improvement in SNCV and thermal
hypoalgesia in erlotinib-treated diabetic Swiss Webster
mice was not observed in our previous study using
C57Bl/6 mice [21]. Whether this observation is attrib-
utable to differences between the mouse strains is un-
clear. Nonetheless, these data support that Erb B2
signaling may contribute to glial cell dysfunction in
DPN.
Assessing changes in intraepidermal nerve fiber dens-
ity (IENFD) is emerging as a powerful technique for ac-
curately diagnosing and staging the onset of a small fiberdiabetic mice. Swiss Webster mice were rendered diabetic and after
essed weekly (*, p < 0.05 versus time-matched Veh + Veh; ^, p < 0.05
a subgroup of animals (n = 4 per group) after 12 weeks of diabetes
eeks of diabetes, animals were given vehicle or 25 mg/kg erlotinib
arrow) for the final four weeks (n = 8-12 per group). Erlotinib
e deficits in both MNCV and SNCV compared to vehicle treated
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We processed the plantar surface of the hind paws and
stained the nerve fibers with an antibody against protein
gene product 9.5 (PGP 9.5), which is a cytosolic ubiqui-
tin C-terminal hydroxylase specifically expressed in neu-
rons. The PGP 9.5-positive nerve fibers that crossed the
epidermal/dermal junction were counted to quantify dis-
tal nerve innervation (Figure 2A and B). As anticipated,
12 weeks of diabetes significantly decreased IENFD but
fiber loss was not significantly greater after 21 weeks ofFigure 2 Inhibition of Erb B2 improved IENFD in DPN mice. Footpad s
12 (n = 4 per group) or 21 weeks (n = 6–8 per group) of treatment. (A): Rep
mice treated with vehicle (Veh) or erlotinib (Erl). Nerve fibers immunopositi
epidermal cells were stained purple by hematoxylin. (B): Quantification dem
to drug administration and erlotinib treatment induced a partial recovery indiabetes. However, erlotinib treatment partially reversed
the diabetes-induced loss of the largely unmyelinated
intra-epidermal nerve fibers. Though the increase in
IENFD in erlotinib-treated diabetic mice may contribute
to the increased sensitivity to noxious thermal stimuli,
improved thermal sensitivity can occur in the absence of
an increase in epidermal fibers [25,26].
After 12 and 21 weeks of diabetes, fasting blood glu-
cose (FBG) levels and HbA1c were increased. As
expected, diabetic mice showed a loss of body weightamples were collected from the plantar surface of the hind paws after
resentative images of IENFD in non-diabetic (Veh) and diabetic (STZ)
ve for PGP 9.5 are stained red by the chromagen (arrows) and
onstrated a significant loss of nerve innervation in diabetic mice prior
fiber loss (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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(Table 1) and erlotinib treatment did not affect FBG or
body weight compared to vehicle-treated diabetic mice.
These results indicate that the effect of erlotinib on im-
proving the diabetes-induced nerve deficits in both mye-
linated and unmyelinated nerve fibers were not related to
correction of the systemic hyperglycemia, consistent with
our previous observation in diabetic C57Bl/6 mice [21].Diabetes differentially alters the expression of NRG1
isoforms in sural nerve
Though Erb B2 activity can contribute to DPN, it is un-
known whether this may be associated with changes in
the expression of NRG1 isoforms which can promote SC
differentiation or dedifferentiation. Sciatic and sural
nerves were isolated from control and diabetic mice,
protein lysates were separated by SDS-PAGE and probed
with two different NRG1 Type III antibodies. Using a
previously reported strategy [12], we raised a polyclonal
antibody against a peptide sequence near the distinct
cysteine-rich domain (CRD) in the NRG1 Type III iso-
form. Immunoblot of sciatic nerve extracts with this
antibody detected a prominent band at about 75 kDa
(Figure 3A). This band represents the N-terminal frag-
ment after cleavage and is consistent with the protein
size previously reported [27]. As a complementary ap-
proach, we also used a well characterized commercial
NRG1 Type III antibody that was raised against a region
within the C-terminal domain of NRG1 Type III (SMDF,
sensory and motor neuron derived factor) and detects a
band at about 65 kDa.
To confirm antibody specificity, 0.5 μg/ml of the
NRG1 Type III antibody was preabsorbed with the im-
munizing peptide in a 1:50 to 1:200 mass ratio prior to
immunoblot analysis of sciatic nerve lysates (Figure 3B).
The immunizing peptide decreased the amount of
NRG1 Type III present at 75 kDa but had no effect on
the band present at 50 kDa, indicating it is non-
specifically recognized by the antibody. Though the
identity of the minor 37 kDa band in Figure 3A isTable 1 Body weights, FBG and HbA1c values from the
Swiss Webster mice
Week Treatment FBG (mg/dl) Weight (g) (n) HbA1c (%) (n)
Week 12 Veh 112 ± 21 37.2 ± 5.4 10 5.0 ± 0.4 6
STZ 595 ± 12* 30.6 ± 3.7* 11 12.9 ± 0.2* 7
Week 21 Veh + Veh 121 ± 26 42.6 ± 5.4 8 5.1 ± 0.1 3
Veh + Erl 104 ± 17 43.4 ± 2.7 8 5.0 ± 0.2 3
STZ + Veh 545 ± 106* 34.5 ± 3.5* 8 10.2 ± 1.7* 4
STZ + Erl 584 ± 40# 37.0 ± 5.5# 6 11.4 ± 1.1# 4
*, p < 0.05 vs. Veh or Veh + Veh; #, p < 0.05 vs. Veh + Erlotinib (Erl).unknown, it may represent a degradation product of
NRG1 Type III as it was not consistently detected. Im-
portantly, preabsorbing the peptide to an antibody
against NRG1 Type I (Figure 3C) or the NRG1 Type III
antibody that was raised against a region within the C-
terminal domain of NRG1 Type III (Figure 3D) did not
decrease the detection of these NRG1 isoforms, further
supporting the specificity for the custom antibody
against an N-terminal fragment of NRG1 Type III. Im-
munoblotting for β-actin indicated that similar amounts
of protein were present in each sample. Unfortunately,
we were unable to detect the presence of the 165 kDa
unprocessed NRG1 with any antibodies used in the
current work.
After 9 weeks (Figure 4A) and 12 weeks (Figure 4B) of
diabetes, immunoblot analysis with both antibodies
showed a significant decrease in the 75 kDa and 65 kDa
NRG1 Type III bands in sural nerve (Figure 3D). Simi-
larly, the expression of NRG1 Type III was also de-
creased in sciatic nerve after 9 and 12 weeks of diabetes
(Figure 5A-C). Given the role of axonal NRG1 Type III
in promoting SC differentiation, these data suggest that
diabetes may compromise myelination by decreasing
NRG1 Type III levels. However, a decrease in NRG1
Type III would not be anticipated to stimulate Erb B2
activity in peripheral nerve. Since NRG1 Type I can
stimulate SC dedifferentiation [17], we also investigated
whether altered expression of this isoform is associated
with DPN. After 9 weeks of diabetes, the level of NRG1
Type I was modestly increased in sural nerve but this re-
sponse was more robust after 12 weeks (Figure 6A and B).
However, the levels of NRG1 Type I in diabetic sciatic
nerve remained unchanged at both time points (data
not shown). These data suggest that diabetes can differ-
entially alter the expression of NRG1 isoforms, espe-
cially in the largely sensory sural nerve.
Diabetes decreases erbin expression and increases p42/
p44 MAPK activity
Erbin is an Erb B2 interacting protein that can function
as a negative regulator of receptor signaling, in part by
inhibiting p42/p44 MAPK activity [28]. Thus, a decrease
in erbin expression may also contribute to potential
dysregulation of Erb B2 signaling in diabetic nerve. Dia-
betic sciatic nerve showed a decreased expression of
erbin at 12 and 16 weeks (Figure 7A-D). However, en-
hanced activity of p42/p44 MAPK pathway was only
detected in 16-week diabetic sciatic nerves (Figure 7D).
Though it was difficult to detect erbin in sural nerve, its
level also decreased after 21 weeks of diabetes and this
correlated with an increase in phosphorylation of p42/
p44 MAPK. Treatment with erlotinib treatment signifi-
cantly decreased the extent of MAPK phosphorylation
(Figure 8A and B).
Figure 3 Validation of specificity of the custom NRG1 Type III antibody. (A): Comparison of NRG1 Type III detection using the custom
N-terminal NRG1 Type III polyclonal antibody (left) and a commercial C-terminal NRG1 Type III polyclonal antibody (SMDF, right). (B-D)
Demonstration of the specificity of the N-terminal NRG1 Type III polyclonal antibody. The indicated amounts of the N-terminal NRG1 Type III
antibody (B), a polyclonal antibody against NRG1 Type I (C) or the C-terminal NRG1 Type III antibody (SMDF, D) were preabsorbed with the
immunizing peptide in a 1:50 to 1:200 ratio for 1 hr at 25°C and then used for immunoblot analysis of a sciatic nerve sample. The peptide
specifically decreased the detection of the 75 kDa NRG1 Type III band but had no effect on detecting NRG1 Type I or the 65 kDa C-terminal
NRG1 Type III fragment.
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Our prior work was the first to suggest that altered sig-
naling via Erb B2 can contribute to the onset of DPN
[21] but it was unclear if changes in Erb B2 signaling
may be associated with an altered expression of NRG1.Figure 4 NRG1 Type III was decreased in sural nerve after 9 and 12 w
sural nerves were isolated at 9 (A) or 12 (B) weeks after the induction of d
Type III level was determined by immunoblot using the two antibodies. (C
β-actin and expressed as a fold of the levels in control sural nerves (*, p < 0The current study extends this work and is the first to
demonstrate that diabetes can alter the expression of
NRG1 isoforms in peripheral nerves. While we observed
a reduction in NRG1 Type III levels in both diabetic sci-
atic and sural nerves, the level of NRG1 Type I increasedeeks of diabetes. Mice were treated with vehicle (Veh) or STZ and
iabetes (n = 6–7 per group). Protein lysates were prepared and NRG1
): Bands were quantified, NRG1 Type III levels were normalized to
.05 versus Veh; **, p < 0.01 versus Veh).
Figure 5 NRG1 Type III was decreased in sciatic nerve after 9 and 12 weeks of diabetes. Mice were treated with vehicle (Veh) or STZ and
sciatic nerves were isolated at 9 (A) or 12 (B) weeks after the induction of diabetes (n = 6–7 per group). Protein lysates were prepared and NRG1
Type III level was determined by immunoblot using the two antibodies. (C): Bands were quantified, NRG1 Type III levels were normalized to
β-actin and expressed as a fold of the levels in control sciatic nerves (*, p < 0.05 versus Veh; **, p < 0.01 versus Veh).
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ition of Erb B2 with erlotinib partially reversed the sen-
sory deficits associated with prolonged diabetes, the
enhanced expression of NRG1 Type I in diabetic sural
nerves might be sufficient to elevate Erb B2 receptor ac-
tivation and contribute to the progression of DPN.
Moreover, the decreased NRG1 Type III and increased
NRG1 Type I expression observed in diabetic sural
nerve (but not in diabetic sciatic nerves) implies that
distal and more thinly myelinated fibers may be moreFigure 6 NRG1 Type I was increased in sural nerves after 9 and 12 we
control and diabetic mice (n = 6–7 per group). Protein lysates were prepare
Abcam NRG1 Type I antibody. (B): Bands were quantified, NRG1 Type I leve
control sural nerves (*, p < 0.05 versus Veh).sensitive to early disruption of NRG1 signaling. This
would be consistent with recent results showing a
greater severity of oxidative stress in distal sural nerve
compared to sciatic nerve [29].
NRG1 Type III is a membrane-anchored precursor
protein which needs to be proteolytically processed to
become an active signaling molecule. The β-secretase
BACE1 (β-site amyloid precursor protein cleaving
enzyme 1) and the α-secretase TACE (tumor necrosis
factor-α-converting enzyme) are two enzymes thateks of diabetes. (A): Sural nerves were isolated from 9 and 12-week
d and NRG1 Type I levels were determined by immunoblot using the
ls were normalized to β-actin and expressed as a fold of the levels in
Figure 7 Erbin was decreased and p42/p44 MAPK activity enhanced in diabetic sciatic nerve. Sciatic nerves were isolated from 9, 12
(A) and 16-week (C) control and diabetic mice (n = 8–9 per group). Protein lysates were prepared and Erbin levels and p42/p44 MAPK (pErk)
levels were determined by immunoblot. Quantification demonstrated a significant decrease of Erbin levels (B) and an increase in p42/p44 MAPK
activation at 16 weeks (D). (*, p < 0.05 versus Veh; **, p < 0.01 versus Veh).
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duces a membrane-anchored, N-terminal fragment that
promotes myelination [30], whereas TACE cleaves NRG1
Type III in the EGF-like domain and inactivates it,
resulting in hypomyelination [31]. BACE cleavage also
produces the C-terminal fragment which can be degraded
by γ-secretase. Though the C-terminal fragment is not ne-
cessary for myelination [32], it may be translocated to the
nucleus of neurons and can repress apoptosis and pro-
mote survival [33]. Diabetes-induced changes in the ex-
pression of NRG1 Type III produced by BACE cleavage
were verified using two antibodies which targeted either
the CRD located within the ~75 kDa N-terminal fragment
or an epitope within the C-terminal fragment. Interest-
ingly, we did not consistently observe the presence of un-
processed NRG1 Type III in nerves from either control or
diabetic mice. This suggests that the decrease in the ex-
pression of the N- and C-terminal fragments of NRG1
Type III were not due to a decrease in proteolytic process-
ing. Thus, changes in the rate of transcription and/or
translation may contribute to the decrease in NRG1 Type
III. However, we also observed an increase in NRG1 Type
I in diabetic sural nerve. Since both isoforms are the prod-
uct of alternative splicing of a single transcript, it is pos-
sible that diabetes-induced changes in mRNA processing
may alter the isoform expression pattern. In this regard,
diabetes has been shown to alter expression of transcrip-
tional variants of the Slo gene that may contribute toerectile dysfunction [34]. However, diabetes may have tis-
sue specific effects on the expression of NRG1 isoforms.
For example, the levels of NRG1 Type I were decreased in
diabetic rats with cardiomyopathy [35] and impaired sig-
naling through the NRG1/Erb B cassette may contribute
to the pathogenesis of diabetic cardiomyopathy, increasing
susceptibility to heart failure [36].
The degeneration of sensory neurons in DPN is clearly
associated with an alteration in neurotrophic support
and disrupted NRG-1/Erb B2 signaling, presumably in
SCs, may be interconnected with altered neurotrophism.
BDNF is released from SCs, is decreased in diabetic rats
[37] and treatment with BDNF prevented nerve conduc-
tion slowing and damage to large motor fibers [38]. A
clear relationship exists between BDNF and NRG1 signal-
ing since BDNF can also stimulate the secretion of soluble
forms of NRG1 [39] whereas transgenic inhibition of en-
dogenous Erb B2 via expression of a dominant-negative
Erb B4 in non-myelinating SCs was sufficient to decrease
the expression of BDNF [14]. Though it remains unclear
whether changes in BDNF levels may have contributed to
the altered expression of NRG1 isoforms observed in dia-
betic nerve in the current study, elucidating the effect of
diabetes on the activity of neurotrophins and neuregulins
in dedifferentiating and regenerating SCs may provide
fundamental insight into the potential for pharmacologic-
ally regulating Erb B2 signaling at specific disease stages
to improve nerve function. Lastly, recent data also
Figure 8 Inhibition of Erb B2 with erlotinib suppressed diabetes-induced p42/p44 MAPK pathway activation in sural nerves. (A): Sural
nerves were isolated from vehicle or erlotinib-treated control and diabetic mice (n = 3–4 per group) at week 21. Protein lysates were prepared
and erbin levels and p42/p44 MAPK (pErk) levels were determined by immunoblot. (B): Quantification demonstrated a significant decrease of
erbin and an increase in p42/p44 MAPK activation in vehicle-treated diabetic mice. Erlotinib treatment suppressed p42/p44 MAPK activation in
erlotinib-treated diabetic mice (*, p < 0.05; **, p < 0.01).
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negatively regulate the expression of SC-derived NRG1
Type I [40]. Although these results were obtained in the
context of a decrease in NRG1 Type III due to axonal loss
following nerve crush, axonal loss is not a hallmark of the
rather early stage of DPN modeled in our study. Thus, a
diabetes-induced alteration in the expression of NRG1
Type III without frank axonal loss may be sufficient to
promote the expression of NRG1 Type I. However, add-
itional work is required to determine if the negative regu-
lation of NRG1 Type I expression by axonal NRG1 Type
III may be recapitulated following a peripheral nerve in-
jury that is solely metabolic.
Erbin functions as an adapter protein that binds to Erb
B2 and it plays an important role in myelination since
erbin knockout mice have a decrease in Erb B2 levels
and NRG1-induced myelination [20,41]. Erbin also
serves as a negative regulator of p42/p44 MAPKsignaling by disrupting the interaction between Ras and
Raf [28,42]. Consistent with this relationship, diabetes
decreased erbin levels in sciatic and sural nerve and this
correlated with an increase in the activity of p42/p44
MAPK. Although erlotinib treatment inhibited the acti-
vation of p42/p44 MAPK in sural nerve, without in-
creasing erbin expression, it is not possible to directly
link this change in MAPK activity to the improved sen-
sory endpoints following erlotinib treatment since the
drug would be expected to blunt all signaling through
Erb B2. Though activation of the MAPK pathway has
been associated with demyelination [18,43], myelin loss
is not a hallmark of DPN in rodent models. Therefore,
the activation of this pathway is either of insufficient
magnitude and duration to promote demyelination in
rodent nerve or contributes to other aspects of DPN.
However, the contribution of p42/p44 MAPK activity to
DPN in both rodent and human DPN is unclear and
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biopsies obtained from diabetic patients undergoing am-
putations [44].
Conclusions
In summary, our data support that diabetes may alter
Erb B2 signaling in peripheral nerve by altering the bal-
ance in NRG1 isoform expression and decreasing the ex-
pression of erbin, an adapter protein that can function
as a negative regulator of p42/p44 MAPK signaling via
Erb B2. Though a limitation of our study is that we can
not ascertain if changes in NRG1 isoforms are necessary
or sufficient to contribute to DPN, altered signaling
through the NRG1-Erb B2 ligand/receptor pair may con-
tribute to dysfunction of both myelinated and unmyelin-
ated fibers since diabetic mice treated with erlotinib
exhibited an improvement in both mechanical and ther-
mal sensitivity. Given the complex role of neuregulins in
controlling both myelination and demyelination, these
data suggest that an altered neuregulinism may contrib-
ute to myelin pathologies that develop in human DPN.
Methods
Reagents and antibodies
Streptozotocin (STZ) was obtained from Sigma-Aldrich (St.
Louis, MO). N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-
4-quinazolinamine (erlotinib) was provided by OSI Pharma-
ceuticals (Melville, NY). NRG1 Type III polyclonal antibody
was produced in rabbits by Chi Scientific (Maynard,
MA) using the CIAGLKWVFVDKIFEYDSPTHL peptide
of NRG1 Type III as the immunizing antigen [12].
CIAGLKWVFVDKIFEYDSPTHL peptide was synthesized
by Selleck Chemicals (Houston, TX). A commercial NRG1
Type III antibody (SMDF C-16) and horseradish peroxid-
ase–conjugated secondary antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). NRG1 Type
I (ab27303) and erbin (ab55930) antibodies were pur-
chased from Abcam (Cambridge, MA). Other antibodies
and their sources were: β-actin antibody (#691002, MP
Biomedicals, Solon, OH); phospho-MAPK 1/2 (#9101)
and total MAPK 1/2 (#9102) antibodies (Cell Signaling,
Boston, MA).
Induction of diabetes and drug treatment
Swiss Webster mice were obtained from Harlan Labora-
tories (Indianapolis, IN) and eight-week old mice were
rendered diabetic with freshly prepared STZ given by in-
traperitoneal injection at 100 mg/kg for two consecutive
days. One week after the last injection, mice were fasted
for 6 hrs and blood was obtained from the tail vein. Mice
with a fasting blood glucose ≥ 290 mg/dl (16 mmol/l) were
deemed diabetic (One-Touch Ultra glucometer). All ani-
mals were maintained on a 12-h light/dark cycle with ad
libitum access to water and Purina diet 5001 rodent chow.To inhibit Erb B2, erlotinib was dissolved in 0.1 mM
Captisol and given at 25 mg/kg via intraperitoneal injec-
tion either once or twice per week. Final levels of fasting
blood glucose and glycated hemoglobin (HbA1c, A1C
Now+) were determined immediately before euthanizing
the animals. All animal procedures were performed in ac-
cordance with protocols approved by the Institutional
Animal Care and Use Committee and in compliance with
standards and regulations for care and use of laboratory
rodents set by the National Institutes of Health.
Measure of sensory hypoalgesia and nerve conduction
velocities (NCV)
Mechanical and thermal sensitivity were measured as
previously described using a Dynamic Plantar Aesthesio-
meter (Stoelting, Wood Dale, IL) and a Hargreaves
Analgesiometer, respectively [26]. Withdrawal force
(grams) and paw withdrawal latency (seconds) are the
average of three to four trials taken from alternating feet
with 5-min periods between testing. Motor and sensory
nerve conduction velocities were assessed in deeply
anesthetized mice as previously detailed [21]. Whole
body (rectal probe) and near nerve temperatures (sub-
cutaneous probe) of anesthetized mice were maintained
at 36–37°C using a heating pad and heat lamp.
Immunoblot analysis
Peripheral nerves were homogenized in 0.2-ml lysis buf-
fer (50 mmol/l Tris–HCl, pH 7.5, 1 mmol/l EDTA, 1%
Nonidet P-40, 0.5% deoxycholate, 1 mmol/l Na3VO4,
150 mmol/l NaCl, 0.5 mmol/l sodium molybdate, 40
mmol/l NaF, 10 mmol/l β-glycerophosphate, and 1X
Complete Protease inhibitors) (Roche Diagnostics) with
the aid of a Polytron fitted with a micro tissue tearor.
Cell debris was sedimented at 10,000 × g for 5 min at 4°C,
and the protein concentration of the supernatant was de-
termined. Proteins were separated by SDS-PAGE and
transferred onto nitrocellulose for immunoblot analyses.
Immunoblots were quantified by densitometry with the
aid of ImageJ software and the level of the proteins of
interest was normalized to β-actin unless otherwise stated.
Changes in protein expression are expressed as a percent
of the control values.
Peptide competition assay
Sciatic nerves from untreated adult mice were homoge-
nized in lysis buffer, proteins were separated by SDS-
PAGE and transferred onto nitrocellulose for immunoblot
analyses. The various NRG1 antibodies were preabsorbed
with buffer or the immunizing peptide at a 1:50, 1:100 or
1:200 mass ratio by incubation for 1 hr at 25°C prior to
their use for detecting NRG1 isoforms in the nerve lysate
by immunoblot analysis.
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The integument of the plantar surface of both hind paws
was dissected and placed in Zamboni’s fixative overnight.
Tissues were then rinsed in PBS at 4°C, cryoprotected in
30% sucrose overnight, embedded in OCT, frozen on
dry ice, and stored at −80°C. Frozen tissues were sec-
tioned at 30 μm, placed on Fisherbrand Superfrost Plus
microscope slides and stored at −80°C. Immunohisto-
chemistry was performed using the Vectastain Elite
ABC-Peroxidase kit for rabbit IgG (Vector Laboratories,
Burlingame, CA) and an anti PGP 9.5 antibody (AbD
Serotec, Oxford, UK). Sections were then counterstained
by NovaRED peroxidase substrate solution (Vector
Laboratories, Burlingame, CA) and with hematoxylin. A
total of twelve images per animal were captured on a
Zeiss LSM 510 Meta confocal microscope for quantifica-
tion. Single nerve fibers crossing the dermal/epidermal
junction were counted from each image. The IENF dens-
ity was calculated by the number of fibers counted di-
vided by the length of the dermal/epidermal junction
(fibers/mm).
Statistical analysis
Data are presented as means ± SEM. After verifying
equality of variance, differences between treatments
were determined using a one-way or two-way ANOVA.
Differences between group means were ascertained
using Tukey’s test.
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